Ezetimibe
| Evidence Level: L1 | Predicted Indications: 4 |
Table of Contents
Ezetimibe: From Hypercholesterolemia to Hyperlipoproteinemia
One-Sentence Summary
Ezetimibe is a cholesterol absorption inhibitor originally used to treat hypercholesterolemia (alone or combined with a statin). The TxGNN model predicts it may also be effective for Hyperlipoproteinemia, with 50 clinical trials and 19 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypercholesterolemia (globally established use; no India-specific approved indication text available — see Market status below) |
| Predicted New Indication | Hyperlipoproteinemia |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L1 |
| India Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed DrugBank mechanism-of-action text is flagged as a data gap in this evidence pack. However, based on well-established public pharmacology, Ezetimibe is a selective cholesterol absorption inhibitor that targets the NPC1L1 (Niemann-Pick C1-Like 1) transporter on the brush border of the small intestine, blocking absorption of both dietary and biliary cholesterol and thereby lowering LDL cholesterol (LDL-C).
Hyperlipoproteinemia is a broad classification covering disorders of lipoprotein metabolism, including various forms of hypercholesterolemia and mixed dyslipidemia. This overlaps substantially with Ezetimibe’s original indication both mechanistically and in the patient populations treated. In fact, Ezetimibe is already widely used clinically — alone or combined with statins, fenofibrate, or niacin — across multiple hyperlipidemia subtypes (mixed hyperlipidemia, familial hypercholesterolemia), so the TxGNN prediction is consistent with existing clinical practice rather than a novel mechanistic leap.
The evidence level for this indication is L1 (≥2 completed Phase 3 RCTs), reflecting a large and mature body of clinical trial evidence, including combination-therapy RCTs and multi-thousand-patient post-marketing surveillance studies in Japan and the Philippines.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00704444 | N/A (PMS) | Completed | 11,332 | 12-week Japanese post-marketing surveillance of Zetia (ezetimibe) monotherapy and combination therapy |
| NCT00705211 | N/A (PMS) | Completed | 1,794 | 52-week long-term Japanese post-marketing surveillance of Zetia monotherapy and combination therapy |
| NCT00704535 | N/A (PMS) | Completed | 4,105 | Post-marketing safety/efficacy surveillance of ezetimibe among Filipino patients with hypercholesterolemia |
| NCT00093899 | Phase 3 | Completed | 611 | Cholesterol-lowering efficacy of ezetimibe/simvastatin + fenofibrate in mixed hyperlipidemia |
| NCT00092560 | Phase 3 | Completed | 587 | Efficacy and safety of fenofibrate + ezetimibe coadministration in mixed hyperlipidemia |
| NCT00552097 | Phase 3 | Completed | 720 | ENHANCE trial: ezetimibe + high-dose simvastatin vs simvastatin alone on carotid atherosclerosis progression in heterozygous FH |
| NCT00271817 | Phase 3 | Completed | 1,220 | Efficacy and safety of ezetimibe/simvastatin + extended-release niacin in Type IIa/IIb hyperlipidemia |
| NCT03847506 | Phase 4 | Completed | 127 | Ezetimibe/rosuvastatin combination tablets vs candesartan/amlodipine combination in hypertension + hyperlipidemia |
| NCT00655265 | Phase 4 | Completed | 86 | Colesevelam as add-on to statin + ezetimibe in familial hypercholesterolemia patients not at LDL-C target |
| NCT00652431 | Phase 1 | Completed | 18 | Bi-directional interaction study between Vytorin (ezetimibe/simvastatin) and Niaspan (extended-release niacin) |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40347969 | 2025 | RCT (Phase 3) | Lancet | TANDEM trial: fixed-dose obicetrapib + ezetimibe combination for LDL-C reduction |
| 41206969 | 2026 | RCT | JAMA | Oral PCSK9 inhibitor enlicitide in heterozygous FH; ezetimibe-era background therapy context |
| 37762244 | 2023 | Review | International Journal of Molecular Sciences | Pathophysiology, diagnosis, and treatment of postprandial hyperlipidemia |
| 33766264 | 2021 | Review | Journal of the American College of Cardiology | New and emerging LDL-C/ApoB-lowering therapies, including ezetimibe-based combinations |
| 35593194 | 2022 | Review | Journal of Cardiovascular Pharmacology and Therapeutics | Comprehensive review of PCSK9 inhibitors, contextualized against ezetimibe/statin therapy |
| 40682836 | 2025 | Review | Molecular Medicine Reports | Research advances in current drugs targeting hyperlipidemia |
| 25939291 | 2015 | Review | Cardiology Clinics | Familial hypercholesterolemia treatment landscape including ezetimibe |
| 38599725 | 2024 | Review | Indian Heart Journal | Familial hypercholesterolemia epidemiology and management in the Indian population |
| 34480646 | 2021 | Review | Current Cardiology Reports | Global burden and management approaches for familial hypercholesterolemia |
| 29219151 | 2017 | Review | Nature Reviews Disease Primers | Familial hypercholesterolaemia: pathophysiology and treatment overview |
India Market Information
Ezetimibe is currently not marketed in India under this evidence pack’s regulatory data source (0 registrations, no license records available). No product name, dosage form, or approved indication text can be reported at this time.
Safety Considerations
Drug Interactions: A DDI query returned 171 total interactions. The interactions classified at Moderate severity are:
- Chenodeoxycholic acid
- Eluxadoline
- Rosuvastatin
- Simvastatin
An additional list of interactions with unclassified (“Unknown”) severity was returned (e.g., Calcitriol, Pantoprazole, Glimepiride, Mesalazine, Doxycycline, Clotrimazole, Acarbose, Morphine, Metformin, Omeprazole), but clinical significance for these could not be determined from available data.
Detailed prescribing warnings and contraindications are not available in this evidence pack (data gap, flagged as Blocking severity — see Conclusion below); please refer to the official package insert once available.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The predicted indication (Hyperlipoproteinemia) is supported by an L1 evidence level — multiple completed Phase 3 RCTs plus large-scale post-marketing surveillance (>10,000 patients) — and is mechanistically and clinically continuous with Ezetimibe’s established use in hypercholesterolemia/dyslipidemia. However, the drug is not currently marketed in India and key local safety documentation is missing, so progression should be gated on closing those specific gaps rather than treated as a green light.
To proceed, the following is needed:
- TFDA/CDSCO package insert (warnings and contraindications) — currently a Blocking data gap (DG001)
- Formal DrugBank-sourced mechanism-of-action confirmation — currently a High-severity data gap (DG002), though public pharmacology is well established
- India market entry/registration assessment, since the drug currently has zero local licenses
- Clinical review of the Moderate-severity DDIs (Chenodeoxycholic acid, Eluxadoline, Rosuvastatin, Simvastatin) in the context of the proposed hyperlipoproteinemia population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.